Study record managers: refer to the Data Element Definitions if submitting registration or results information.
|1||NCT01216683||Active, not recruiting||Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma||
||Other / NIH||
||250||All||18 Years to 120 Years (Adult, Senior)||NCT01216683||E2408
|December 2010||April 30, 2018||April 2023||October 7, 2010||December 14, 2017||